文献速递心脑血管急症

冠状动脉旁路移植术中的桡动脉移植物与大隐静脉移植物比较

Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery.
PubMed 文献 · N Engl J Med · 2018-04-30
一句话结论患者水平合并分析显示,CABG使用桡动脉移植物较大隐静脉移植物降低5年不良心脏事件(HR 0.67)并提高桥血管通畅率(HR 0.44)。

该研究为6项随机对照试验的患者水平合并分析,共纳入1036例CABG患者(桡动脉组534例,大隐静脉组502例),比较桡动脉移植物与大隐静脉移植物。主要终点为死亡、心肌梗死或再次血运重建的复合终点,次要终点为随访血管造影的桥血管通畅率。平均随访60±30个月,桡动脉组主要终点发生率显著低于大隐静脉组(HR 0.67,95%CI 0.49-0.90,P=0.01),随访血管造影(平均50±30个月)显示桡动脉组桥血管闭塞风险显著更低(HR 0.44,95%CI 0.28-0.70,P<0.001)。桡动脉组心肌梗死发生率名义上更低(HR 0.72,95%CI 0.53-0.99,P=0.04),再次血运重建率更低(HR 0.50,95%CI 0.40-0.63,P<0.001),但全因死亡无显著差异(HR 0.90,95%CI 0.59-1.41,P=0.68)。

要点

  • 6项RCT患者水平合并分析共1036例CABG患者,桡动脉组534例,大隐静脉组502例,平均随访60±30个月。
  • 桡动脉组主要复合终点(死亡、心肌梗死或再次血运重建)发生率显著低于大隐静脉组:HR 0.67(95%CI 0.49-0.90,P=0.01)。
  • 随访血管造影(平均50±30个月)显示桡动脉组桥血管闭塞风险显著更低:HR 0.44(95%CI 0.28-0.70,P<0.001)。
  • 桡动脉组再次血运重建率更低(HR 0.50,95%CI 0.40-0.63,P<0.001),心肌梗死发生率名义上更低(HR 0.72,95%CI 0.53-0.99,P=0.04)。
  • 全因死亡在大隐静脉组与桡动脉组间无显著差异:HR 0.90(95%CI 0.59-1.41,P=0.68)。

适用人群与场景

  • 纳入6项随机对照试验的CABG患者,共1036例(桡动脉组534例,大隐静脉组502例),原文未报告具体纳入与排除标准。

研究设计与关键结果

  • 研究类型为6项随机对照试验的患者水平合并分析,共1036例患者(桡动脉组534例,大隐静脉组502例),原文未报告中心数。
  • 主要终点为死亡、心肌梗死或再次血运重建的复合终点,平均随访60±30个月,桡动脉组发生率显著低于大隐静脉组:HR 0.67(95%CI 0.49-0.90,P=0.01)。
  • 次要终点为随访血管造影的桥血管通畅率,平均随访50±30个月,桡动脉组桥血管闭塞风险显著低于大隐静脉组:HR 0.44(95%CI 0.28-0.70,P<0.001)。
  • 心肌梗死发生率桡动脉组名义上低于大隐静脉组:HR 0.72(95%CI 0.53-0.99,P=0.04)。
  • 再次血运重建率桡动脉组低于大隐静脉组:HR 0.50(95%CI 0.40-0.63,P<0.001)。
  • 全因死亡在大隐静脉组与桡动脉组间无显著差异:HR 0.90(95%CI 0.59-1.41,P=0.68)。

证据类型、等级与局限

  • 证据类型为6项随机对照试验的患者水平合并分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在CABG患者中,与大隐静脉移植物相比,使用桡动脉移植物与5年随访时更低的不良心脏事件发生率和更高的桥血管通畅率相关。
  • 原文未据此给出适用人群、不适用人群或具体操作推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of radial-artery grafts for coronary-artery bypass grafting (CABG) may result in better postoperative outcomes than the use of saphenous-vein grafts. However, randomized, controlled trials comparing radial-artery grafts and saphenous-vein grafts have been individually underpowered to detect differences in clinical outcomes. We performed a patient-level combined analysis of randomized, controlled trials to compare radial-artery grafts and saphenous-vein grafts for CABG.

METHODS: Six trials were identified. The primary outcome was a composite of death, myocardial infarction, or repeat revascularization. The secondary outcome was graft patency on follow-up angiography. Mixed-effects Cox regression models were used to estimate the treatment effect on the outcomes.

RESULTS: A total of 1036 patients were included in the analysis (534 patients with radial-artery grafts and 502 patients with saphenous-vein grafts). After a mean (±SD) follow-up time of 60±30 months, the incidence of adverse cardiac events was significantly lower in association with radial-artery grafts than with saphenous-vein grafts (hazard ratio, 0.67; 95% confidence interval [CI], 0.49 to 0.90; P=0.01). At follow-up angiography (mean follow-up, 50±30 months), the use of radial-artery grafts was also associated with a significantly lower risk of occlusion (hazard ratio, 0.44; 95% CI, 0.28 to 0.70; P<0.001). As compared with the use of saphenous-vein grafts, the use of radial-artery grafts was associated with a nominally lower incidence of myocardial infarction (hazard ratio, 0.72; 95% CI, 0.53 to 0.99; P=0.04) and a lower incidence of repeat revascularization (hazard ratio, 0.50; 95% CI, 0.40 to 0.63; P<0.001) but not a lower incidence of death from any cause (hazard ratio, 0.90; 95% CI, 0.59 to 1.41; P=0.68).

CONCLUSIONS: As compared with the use of saphenous-vein grafts, the use of radial-artery grafts for CABG resulted in a lower rate of adverse cardiac events and a higher rate of patency at 5 years of follow-up. (Funded by Weill Cornell Medicine and others.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Gaudino M, Benedetto U, Fremes S, et al. Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery. N Engl J Med. 2018. PMID: 29708851. doi:10.1056/NEJMoa1716026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。